DTB Navarre
@DTB_Navarre
Followers
298
Following
7
Media
49
Statuses
268
Bulletin to provide independent information on pharmacotherapy, improve patient care and contribute to the sustainability of the public health system
Spain
Joined December 2011
📢📢 Therapeutic personalisation I: practical aspects of pharmacokinetic monitoring 📢📢 https://t.co/Oj083nt2ev
@mariacalvoar @salud_na
0
0
0
📢📢Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease https://t.co/rs3oQpvR32
@BITNavarra @salud_na
0
1
0
📢📢 New drug assessment report 📢📢 Tirzepatide. Unknowns regarding its efficacy in morbidity and mortality @salud_na
https://t.co/ajGhX5HuE0
0
0
0
📢📢Surrogate outcomes and fast-track drug approval. Towards reversing the burden of proof? https://t.co/PDSdKWwlXv
@BITNavarra @salud_na
0
0
0
📢📢Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity https://t.co/wXNXMJTw7E
@BITNavarra @salud_na
0
2
3
(Cochrane Library) Blood pressure targets for hypertension in people with chronic renal disease https://t.co/wcD07pFx5q
0
0
1
📢New drug assessment report: FINERENONE IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES https://t.co/3OjsRNWLAE
0
2
3
📢📢New drug assessment report 📢📢 Dapagliflozin for heart failure with mildly reduced or preserved ejection fraction https://t.co/qT6nBvth1F
0
0
0
📢📢New drug assessment report📢📢 Icosapent Ethil (Omega-3) for hypertriglyceridemia https://t.co/EtHLgArANh
0
0
0
📢📢New drug assessment report📢📢 Use of fluid therapy in clinical practice https://t.co/VDijRyyw99
@BITNavarra
0
2
2
Long-term effectiveness and safety of tolvaptan in autosomal dominant ... https://t.co/51DwmLYKqH
0
0
0
📢📢New drug assessment report📢📢 Bempedoic Acid and Bempedoic Acid/Ezetimibe: a mystery for the treatment of hypercholesterolaemia https://t.co/4677tucY2H
0
3
4
(dtbn) Long-acting injectable antipsychotics in schizophrenia 💉💉 https://t.co/Tw5Nmq6UHH
0
2
3
📢📢New drug assessment report📢📢EMPAGLIFLOZIN FOR SYMPTOMATIC, CHRONIC HEART FAILURE. Yes, but... for much selected patients. https://t.co/Au4xMyWBUf
0
0
1
We support the prohibition of Direct to Consumer Advertising of Prescription Medicines (DTCA-PM) in New Zealand https://t.co/ASCwJHOVYm
0
0
1
📢📢New drug assessment report: vericiguat in heart failure
0
0
3
📢📢New drug assessment report: dapagliflozin in chronic kidney disease https://t.co/uVRLx8J1hm
0
0
0